What is the approval status of Belzutifan in renal clear cell sarcoma? Clinical application analysis

Belzutifan (trade name: Welireg) is an oral HIF-2α inhibitor, mainly used to treat patients with von Hippel–Lindau (VHL) disease-related clear cell renal cell carcinoma (ccRCC), central nervous system hemangioblastoma (CNS hemangioblastomas) and pancreatic neuroendocrine tumors (pNETs). 2023Year12Monday14, the U.S. Food and Drug Administration (FDA) is approved for the treatment of patients with advanced clear cell renal cell carcinoma, specifically those whose disease has progressed after treatment with a PD-1/PD-L1 inhibitor and a VEGF-TKI.

The approval of besetifan was based on the results of the LITESPARK-005 study, an open-label, randomized controlled Phase III clinical trial that enrolled 746 patients with advanced clear cell renal cell carcinoma. Studies have shown that bezotivan is significantly better than everolimus (everolimus) in delaying disease progression, and its progression-free survival (PFS) Risk reduction 25% (HR=0.75, 95% CI, 0.63-0.90, p=0.0008). In addition, the objective response rate (ORR) was 22% with bestifan and 4% with everolimus. These results demonstrate the potential clinical advantage of bezotivan in the treatment of advanced clear cell renal cell carcinoma.

The mechanism of action of Bestifan is to reduce the transcription and expression of genes related to tumor cell proliferation, angiogenesis and tumor growth by inhibitingHIF-2α. HIF-2α plays a key carcinogenic role in clear cell renal cell carcinoma.HIF-2The first inhibitor of α provides a new treatment option for patients with advanced clear cell renal cell carcinoma.

In terms of safety, common adverse reactions of bezutivan include anemia, fatigue, musculoskeletal pain, increased creatinine, lymphopenia, increased aspartate aminotransferase (AST) and alanine aminotransferase (ALT), decreased sodium, increased potassium, etc. Of these, anemia is the most common side effect and may require blood transfusions. Therefore, during treatment, patients need to regularly monitor hemoglobin levels and make dose adjustments or discontinue medication as needed.

In summary, bezutivan, as a new type of HIF-2α inhibitor, provides a new treatment option for patients with advanced clear cell renal cell carcinoma. In the LITESPARK-005 study, it showed better efficacy than existing treatments and has a unique mechanism of action. However, patients need to be closely monitored for possible side effects, particularly anemia, while taking besettivan to ensure the safety and effectiveness of the treatment.

Reference materials:https://www.welireg.com/